Publications by authors named "Nataliya Bogoeva"
Objective: DESTINY-Breast03, a randomised, phase 3 trial, evaluated trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor (HER2)-positive unresectable and/or metastatic breast cancer who progressed on or after treatment with trastuzumab and a taxane. At the current data cut off overall survival analysis, T-DXd demonstrated a substantial improvement in overall survival over T-DM1. This secondary analysis use of DESTINY-Breast03 aimed to further evaluate the treatment differences using quality-adjusted survival time without symptoms or toxicity (Q-TWiST) methods.
View Article and Find Full Text PDFSpinal muscular atrophy (SMA) is a genetic neuromuscular disorder characterized by skeletal muscle weakness and atrophy. Patients with SMA types 1 and 2 develop severe disabilities conferring substantial patient and caregiver burden. Caregiver treatment characteristic preferences are useful for informing treatment choices and improving adherence.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to determine which patients with mild plaque psoriasis (less than 10% body surface area involvement) should receive systemic treatment and to define what constitutes a failure of topical therapy.
- A panel of 45 clinical experts from Japan provided input through two rounds of voting, leading to a consensus on various criteria for systemic treatment eligibility and for defining topical therapy failure.
- Key criteria for systemic treatment eligibility included severe symptoms, psychological distress, locations of difficulty, psoriatic arthritis, and inadequate response to topical treatments; while topical therapy failure was defined by persistent symptoms, low patient satisfaction, and specific severity scores after treatment.
Background: Given the increased availability of data sources such as hospital information systems, electronic health records, and health-related registries, a novel approach is required to develop artificial intelligence-based decision support that can assist clinicians in their diagnostic decision-making and shorten rare disease patients' diagnostic odyssey. The aim is to identify key challenges in the process of mapping European rare disease databases, relevant to ML-based screening technologies in terms of organizational, FAIR and legal principles.
Methods: A scoping review was conducted based on the PRISMA-ScR checklist.